TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01459913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study: NCT02142036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA-approved ATI based targeted therapy
Description: All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
Study: NCT03766269

Intervention type: DRUG
Group type: OTHER
Intervention: Dronabinol
Description: Dronabinol coadministered with patient's existing Baseline Opioid.
Study: NCT05746936

Intervention type: PROCEDURE
Intervention: Roux en-Y gastric bypass
Description: gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis

Intervention type: PROCEDURE
Intervention: Roux en-Y gastric bypass
Description: gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
Study: NCT04065594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP dressing
Description: PRP dressing gel dressings for treatment of chronic ulcer
Study: NCT04016376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVB Protocol
Description: Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVB Protocol
Description: Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PECS-1
Description: For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PECS-1
Description: For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serratus
Description: For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
Study: NCT02232425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06088550

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BCAA
Description: a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine \& 1.25 gm valine).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BCAA
Description: a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine \& 1.25 gm valine).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home-based graded exercise program
Description: home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
Study: NCT01986049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivicaine
Study: NCT01506310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise groups will be advised to walk at least 20-minute a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral therapy and exercise
Description: General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change
Study: NCT03369925

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline supplement
Description: Cognizin
Study: NCT06088550

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home-based graded exercise program
Description: home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
Study: NCT00665353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon
Description: Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
Study: NCT04065594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional ordinary dressing
Description: conventional ordinary dressing for treatment of chronic ulcer
Study: NCT00861016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol succinate prolonged-release tablet and felodipine
Description: a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
Study: NCT01378429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide nasal aerosol
Description: ciclesonide nasal aerosol (74 mcg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02574741

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Therapy
Description: Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Therapy
Description: Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Therapy
Description: Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 50% of the subjects will be randomized to aripiprazole (active study medication)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 50% of the subjects will be randomized to aripiprazole (active study medication)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50% of the subjects will be randomized to placebo (inactive study medication).
Study: NCT01012622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
Description: OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
Study: NCT02784990

Intervention type: BIOLOGICAL
Intervention: Lipase, amylase and CRP (C-reactive protein) dosages
Study: NCT03678532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT03477799

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
Study: NCT02334605

Intervention type: OTHER
Group type: OTHER
Intervention: cold dry air
Description: Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%.

Intervention type: DEVICE
Group type: OTHER
Intervention: hyperosmolar discs
Description: A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.

Intervention type: DEVICE
Group type: OTHER
Intervention: capsaicin nasal spray
Description: 1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
Study: NCT02574741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50% of the subjects will be randomized to placebo (inactive study medication).
Study: NCT00619489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous (IV) infusion
Study: NCT01207245

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin time of administration
Description: Random allocation to time of day of administration of tobramycin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin time of administration
Description: Random allocation to time of day of administration of tobramycin
Study: NCT01697943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction
Study: NCT04419441

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: concomitant administration of radiotherapy and immune checkpoint inhibitor
Study: NCT02030288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Agent Intervention
Description: Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change.
Study: NCT02204852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost+eptifibatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01576185

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Intervention: quizartinib
Description: Via gavage

Intervention type: DRUG
Intervention: sorafenib tosylate
Description: Via gavage
Study: NCT00581451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: oral tablet once daily
Study: NCT04433013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lianhua Qingwen
Description: The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
Study: NCT01188057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG
Description: A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Description: B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
Study: NCT02704611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real tDCS
Description: Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
Study: NCT03751514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bordetella Pertussis B1917
Description: The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bordetella Pertussis B1917
Description: The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Description: To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Description: To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Description: To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile Saline
Description: To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
Study: NCT04098978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Drug Therapy Management
Description: Patients will be seen by pharmacist for collaborative drug therapy management.
Study: NCT04664582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: see intervention group description
Study: NCT00187187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Defibrillator (ICD)
Description: Implantable Defibrillator (ICD)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Defibrillator (ICD)
Description: Implantable Defibrillator (ICD)
Study: NCT02404649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two implant designs in a Sinus Bone Augmentation Procedure
Description: Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two implant designs in a Sinus Floor Elevation Procedure
Description: Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
Study: NCT02182765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amprenavir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Study: NCT01172574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Description: Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
Study: NCT01669213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron
Description: before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: before 5 minutes spinal anesthesia, injection of ondansetron 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: before 5 minutes spinal anesthesia, injection of ondansetron 4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: before 5 minutes spinal anesthesia, injection of normal saline 5 ml